- Conditions
- Healthy
- Interventions
- Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–23
of 23
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatic Impairment
- Interventions
- Relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Solid Tumors
- Interventions
- Relacorilant with nab-paclitaxel
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 1 more
- Conditions
- Healthy, Food-drug Interaction
- Interventions
- Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy
- Interventions
- Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules)
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Cushing Syndrome, Neoplasms
- Interventions
- Dabigatran Etexilate, Relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy
- Interventions
- CORT125134 150 mg, CORT125134 250 mg, CORT125134 dose to be determined
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy
- Interventions
- Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Cushing Syndrome
- Interventions
- relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Relacorilant, Nab-paclitaxel
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
- Conditions
- Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Interventions
- Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more
- Conditions
- Hypercortisolism
- Interventions
- Relacorilant, Placebo
- Drug · Other
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Stanford, California • Torrance, California + 19 more
- Conditions
- Adenocarcinoma, Carcinoma, Pancreatic Ductal
- Interventions
- Relacorilant, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, Relacorilant
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Interventions
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Healthy
- Interventions
- Relacorilant, Placebo to relacorilant, Moxifloxacin
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Healthy
- Interventions
- Relacorilant 350mg, Itraconazole, Relacorilant 300mg
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Cushing Syndrome
- Interventions
- Relacorilant, Placebo
- Drug · Other
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
- Conditions
- Cushing's Syndrome
- Interventions
- CORT125134
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
- Conditions
- Adrenocortical Carcinoma
- Interventions
- Relacorilant, Pembrolizumab
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
- Conditions
- Healthy
- Interventions
- CORT125134
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more